
Behind the FDA Approval: Cabozantinib for Advanced Neuroendocrine Tumors
Jennifer Chan, MD, MPH Clinical Director, Gastrointestinal Cancer Center Director, Program in Carcinoid and Neuroendocrine Tumors Dana-Farber Cancer Institute Boston, MA Patients treated for advanced neuroendocrine tumors (NETs) are at risk of disease …